Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists
Authors:
- 19 December 2018
- journal article
- research article
- Published by Wiley in Neurology and Clinical Neuroscience
- Vol. 7 (1) , 3-21
Abstract
Although rheumatologists, neurologists, and dermatologists see patients with polymyositis (PM) and dermatomyositis (DM), their management appears to vary depending on the physician's specialty. The aim of this study was to establish the treatment consensus among specialists of the three fields to standardize the patient care. We formed a research team supported by a grant from the Ministry of Health, Labor, and Welfare, Japan. Clinical questions (CQ) on the management of PM and DM were raised. A published work search on CQ was performed primarily using PubMed. Using the nominal group technique, qualified studies and results in the published work were evaluated and discussed to reach consensus recommendations. They were sent out to the Japan College of Rheumatology, Japanese Society of Neurology, and Japanese Dermatological Association for their approval. We reached a consensus in 23 CQ and made recommendations, and a decision tree for management was proposed. They were officially approved by the three scientific societies. In conclusion, a multidisciplinary treatment consensus for the management of PM and DM was established for the first time.Keywords
Funding Information
- Ministry of Health, Labour and Welfare
This publication has 184 references indexed in Scilit:
- Abatacept and Sodium Thiosulfate for Treatment of Recalcitrant Juvenile Dermatomyositis Complicated by Ulceration and CalcinosisThe Journal of Pediatrics, 2012
- Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprineArthritis Research & Therapy, 2012
- Coadministration of Cyclosporin a with Prednisolone in Acute Interstitial Pneumonia Complicating Polymyositis/DermatomyositisClinical Medicine Insights: Arthritis and Musculoskeletal Disorders, 2012
- A randomized, pilot trial of etanercept in dermatomyositisAnnals of Neurology, 2011
- Rituximab therapy for myopathy associated with anti–signal recognition particle antibodies: A case seriesArthritis Care & Research, 2010
- Tumor Necrosis Factor Inhibitor–Associated DermatomyositisArchives of Dermatology, 2010
- Mycophenolate mofetil: A possible therapeutic agent for children with juvenile dermatomyositisArthritis Care & Research, 2010
- Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatmentBest Practice & Research Clinical Rheumatology, 2009
- Anti-signal recognition particle autoantibodies: marker of a necrotising myopathyAnnals of the Rheumatic Diseases, 2006
- Long-term outcome in polymyositis and dermatomyositisAnnals of the Rheumatic Diseases, 2006